Concepts (259)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neoplasms | 29 | 2024 | 22023 | 1.750 |
Why?
|
Lung Neoplasms | 25 | 2024 | 13243 | 1.710 |
Why?
|
Medical Oncology | 16 | 2024 | 2309 | 1.370 |
Why?
|
Sexual Dysfunction, Physiological | 3 | 2023 | 351 | 1.200 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 16 | 2024 | 5247 | 1.160 |
Why?
|
Hematology | 3 | 2023 | 241 | 1.150 |
Why?
|
Minority Groups | 9 | 2024 | 1198 | 1.100 |
Why?
|
Physicians, Women | 3 | 2023 | 491 | 1.080 |
Why?
|
Immunotherapy | 8 | 2024 | 4626 | 0.900 |
Why?
|
Physicians | 6 | 2024 | 4583 | 0.880 |
Why?
|
Medical Tourism | 1 | 2023 | 50 | 0.860 |
Why?
|
Vaginal Diseases | 1 | 2023 | 103 | 0.840 |
Why?
|
Weather | 1 | 2023 | 227 | 0.810 |
Why?
|
Thoracic Neoplasms | 1 | 2024 | 266 | 0.780 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2024 | 255 | 0.770 |
Why?
|
Electronics | 1 | 2022 | 319 | 0.740 |
Why?
|
Mentors | 2 | 2023 | 661 | 0.730 |
Why?
|
Medicine | 2 | 2024 | 943 | 0.710 |
Why?
|
Emigrants and Immigrants | 2 | 2023 | 537 | 0.690 |
Why?
|
Breast Neoplasms, Male | 2 | 2020 | 220 | 0.590 |
Why?
|
Humans | 114 | 2024 | 759098 | 0.570 |
Why?
|
Climate Change | 1 | 2023 | 488 | 0.560 |
Why?
|
Clinical Trials as Topic | 6 | 2022 | 8050 | 0.550 |
Why?
|
Delivery of Health Care | 5 | 2023 | 5310 | 0.530 |
Why?
|
Research Personnel | 1 | 2020 | 582 | 0.520 |
Why?
|
Hedgehog Proteins | 1 | 2020 | 769 | 0.510 |
Why?
|
Faculty, Medical | 1 | 2023 | 1185 | 0.480 |
Why?
|
Early Detection of Cancer | 4 | 2023 | 3203 | 0.480 |
Why?
|
Career Choice | 3 | 2023 | 755 | 0.460 |
Why?
|
Latin America | 4 | 2023 | 404 | 0.450 |
Why?
|
Registries | 3 | 2024 | 8435 | 0.440 |
Why?
|
Patient Compliance | 1 | 2023 | 2689 | 0.420 |
Why?
|
Congresses as Topic | 2 | 2023 | 802 | 0.420 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2022 | 1200 | 0.400 |
Why?
|
Education, Medical | 1 | 2024 | 1726 | 0.390 |
Why?
|
Papillomavirus Infections | 1 | 2023 | 1601 | 0.380 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2020 | 2062 | 0.380 |
Why?
|
Women's Health | 1 | 2020 | 2057 | 0.370 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2023 | 2016 | 0.370 |
Why?
|
Names | 1 | 2020 | 52 | 0.370 |
Why?
|
Female | 48 | 2024 | 390174 | 0.370 |
Why?
|
Biomedical Research | 2 | 2020 | 3414 | 0.350 |
Why?
|
Curriculum | 1 | 2023 | 3710 | 0.340 |
Why?
|
Sex Characteristics | 1 | 2020 | 2627 | 0.330 |
Why?
|
Sex Factors | 7 | 2023 | 10515 | 0.330 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2020 | 1708 | 0.320 |
Why?
|
Videoconferencing | 1 | 2021 | 199 | 0.320 |
Why?
|
Breast Neoplasms | 7 | 2023 | 21019 | 0.320 |
Why?
|
Patient Selection | 3 | 2023 | 4268 | 0.310 |
Why?
|
Ventriculoperitoneal Shunt | 1 | 2019 | 186 | 0.310 |
Why?
|
Healthcare Disparities | 7 | 2024 | 3364 | 0.300 |
Why?
|
Nerve Tissue Proteins | 1 | 2020 | 4409 | 0.290 |
Why?
|
Awards and Prizes | 1 | 2021 | 359 | 0.280 |
Why?
|
Teaching Rounds | 1 | 2021 | 275 | 0.280 |
Why?
|
South America | 2 | 2024 | 181 | 0.270 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 11656 | 0.270 |
Why?
|
Societies, Medical | 5 | 2023 | 3890 | 0.260 |
Why?
|
United States | 21 | 2024 | 72238 | 0.250 |
Why?
|
Gynecology | 1 | 2021 | 530 | 0.250 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2019 | 346 | 0.250 |
Why?
|
Esophageal Fistula | 1 | 2015 | 60 | 0.250 |
Why?
|
Gastroenterology | 1 | 2021 | 571 | 0.250 |
Why?
|
Bronchial Fistula | 1 | 2015 | 83 | 0.240 |
Why?
|
Cultural Diversity | 1 | 2018 | 361 | 0.240 |
Why?
|
Cross-Sectional Studies | 7 | 2024 | 25853 | 0.240 |
Why?
|
Radiation Oncology | 1 | 2020 | 560 | 0.240 |
Why?
|
Obstetrics | 1 | 2021 | 668 | 0.230 |
Why?
|
Acetonitriles | 1 | 2024 | 54 | 0.230 |
Why?
|
Social Environment | 1 | 2019 | 1019 | 0.230 |
Why?
|
Breast | 2 | 2020 | 1980 | 0.220 |
Why?
|
Smoking | 1 | 2020 | 9066 | 0.220 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2022 | 4030 | 0.220 |
Why?
|
Committee Membership | 1 | 2023 | 17 | 0.220 |
Why?
|
Male | 31 | 2024 | 358602 | 0.220 |
Why?
|
Pandemics | 5 | 2022 | 8604 | 0.210 |
Why?
|
Educational Status | 1 | 2020 | 2512 | 0.210 |
Why?
|
Caribbean Region | 1 | 2023 | 191 | 0.210 |
Why?
|
Neoplasm Staging | 4 | 2024 | 11125 | 0.210 |
Why?
|
Patient Participation | 1 | 2022 | 1437 | 0.210 |
Why?
|
Workplace | 1 | 2019 | 854 | 0.210 |
Why?
|
Health Services Accessibility | 5 | 2023 | 5366 | 0.210 |
Why?
|
Pancreatic Neoplasms | 1 | 2020 | 5312 | 0.210 |
Why?
|
Burnout, Professional | 1 | 2021 | 699 | 0.210 |
Why?
|
Radiosurgery | 1 | 2022 | 1341 | 0.210 |
Why?
|
Disabled Persons | 1 | 2021 | 1226 | 0.190 |
Why?
|
Demography | 2 | 2024 | 1648 | 0.190 |
Why?
|
Central Nervous System Neoplasms | 1 | 2019 | 908 | 0.190 |
Why?
|
Attitude of Health Personnel | 2 | 2022 | 3864 | 0.190 |
Why?
|
Access to Information | 1 | 2024 | 320 | 0.190 |
Why?
|
Terminal Care | 1 | 2022 | 1758 | 0.180 |
Why?
|
Comorbidity | 2 | 2021 | 10550 | 0.180 |
Why?
|
Practice Guidelines as Topic | 3 | 2024 | 7460 | 0.180 |
Why?
|
Pyridines | 2 | 2024 | 2876 | 0.180 |
Why?
|
Sexual Behavior | 2 | 2023 | 2086 | 0.170 |
Why?
|
Prostatic Neoplasms | 3 | 2023 | 11324 | 0.170 |
Why?
|
Aged | 17 | 2024 | 168615 | 0.170 |
Why?
|
Time Factors | 1 | 2021 | 40083 | 0.160 |
Why?
|
Multiple Myeloma | 2 | 2018 | 5136 | 0.160 |
Why?
|
Public Health | 2 | 2023 | 2656 | 0.160 |
Why?
|
Communication | 2 | 2023 | 3846 | 0.160 |
Why?
|
Family | 2 | 2024 | 3189 | 0.160 |
Why?
|
Retrospective Studies | 11 | 2024 | 80125 | 0.150 |
Why?
|
Palliative Care | 2 | 2023 | 3608 | 0.150 |
Why?
|
Maximum Tolerated Dose | 1 | 2020 | 876 | 0.150 |
Why?
|
Social Justice | 1 | 2022 | 475 | 0.150 |
Why?
|
Travel | 1 | 2023 | 787 | 0.150 |
Why?
|
RNA, Neoplasm | 1 | 2020 | 748 | 0.150 |
Why?
|
Internship and Residency | 2 | 2023 | 5860 | 0.150 |
Why?
|
Anilides | 1 | 2020 | 409 | 0.140 |
Why?
|
Parental Leave | 2 | 2023 | 91 | 0.140 |
Why?
|
Prognosis | 5 | 2023 | 29559 | 0.140 |
Why?
|
Pyrimidines | 2 | 2024 | 2996 | 0.140 |
Why?
|
Health Status Disparities | 1 | 2018 | 1818 | 0.140 |
Why?
|
Pregnancy | 6 | 2024 | 29650 | 0.140 |
Why?
|
Drug Tolerance | 1 | 2018 | 369 | 0.140 |
Why?
|
Job Satisfaction | 2 | 2021 | 535 | 0.130 |
Why?
|
Treatment Refusal | 1 | 2019 | 427 | 0.130 |
Why?
|
Fellowships and Scholarships | 3 | 2023 | 1116 | 0.130 |
Why?
|
Melanoma | 2 | 2019 | 5690 | 0.130 |
Why?
|
Self Report | 2 | 2024 | 3699 | 0.130 |
Why?
|
Middle Aged | 15 | 2024 | 219628 | 0.130 |
Why?
|
Sex Distribution | 1 | 2020 | 2294 | 0.130 |
Why?
|
Heart Diseases | 1 | 2018 | 2799 | 0.120 |
Why?
|
Patient Care | 2 | 2022 | 624 | 0.120 |
Why?
|
Vascular Surgical Procedures | 1 | 2023 | 1471 | 0.120 |
Why?
|
Forecasting | 1 | 2023 | 2928 | 0.120 |
Why?
|
Cost of Illness | 1 | 2024 | 1937 | 0.120 |
Why?
|
International Cooperation | 2 | 2020 | 1435 | 0.110 |
Why?
|
Urban Population | 1 | 2022 | 2015 | 0.110 |
Why?
|
Piperazines | 1 | 2024 | 2516 | 0.110 |
Why?
|
Sirolimus | 1 | 2020 | 1537 | 0.110 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3088 | 0.100 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3208 | 0.100 |
Why?
|
Fertility | 2 | 2024 | 775 | 0.100 |
Why?
|
Education, Medical, Graduate | 3 | 2023 | 2352 | 0.100 |
Why?
|
Spain | 1 | 2023 | 486 | 0.100 |
Why?
|
Hospitals | 2 | 2023 | 3929 | 0.100 |
Why?
|
Caregivers | 1 | 2024 | 2213 | 0.100 |
Why?
|
Lactams | 1 | 2022 | 154 | 0.100 |
Why?
|
Organophosphorus Compounds | 1 | 2022 | 202 | 0.090 |
Why?
|
Rural Population | 1 | 2022 | 2260 | 0.090 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2019 | 9271 | 0.090 |
Why?
|
Quality of Life | 1 | 2022 | 13285 | 0.090 |
Why?
|
Advance Directives | 1 | 2022 | 248 | 0.090 |
Why?
|
Insurance Coverage | 1 | 2022 | 1939 | 0.090 |
Why?
|
Adult | 10 | 2024 | 219353 | 0.090 |
Why?
|
Drug Therapy, Combination | 1 | 2020 | 6490 | 0.090 |
Why?
|
Neoplasm Metastasis | 1 | 2020 | 4883 | 0.080 |
Why?
|
Venezuela | 1 | 2019 | 75 | 0.080 |
Why?
|
Lung | 2 | 2023 | 9980 | 0.080 |
Why?
|
Antineoplastic Agents | 3 | 2024 | 13625 | 0.080 |
Why?
|
Aminopyridines | 1 | 2022 | 564 | 0.080 |
Why?
|
Biopsy | 1 | 2020 | 6770 | 0.080 |
Why?
|
Etoposide | 1 | 2019 | 628 | 0.080 |
Why?
|
Policy | 1 | 2021 | 510 | 0.070 |
Why?
|
Guideline Adherence | 1 | 2018 | 2283 | 0.070 |
Why?
|
Population Surveillance | 1 | 2018 | 2610 | 0.070 |
Why?
|
Immunosuppressive Agents | 1 | 2020 | 4099 | 0.070 |
Why?
|
Indians, North American | 1 | 2020 | 352 | 0.070 |
Why?
|
Prevalence | 2 | 2023 | 15639 | 0.070 |
Why?
|
Analgesics, Opioid | 1 | 2023 | 3759 | 0.070 |
Why?
|
Factor Analysis, Statistical | 1 | 2019 | 998 | 0.070 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2018 | 428 | 0.070 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 7790 | 0.060 |
Why?
|
Decision Making | 1 | 2019 | 3917 | 0.060 |
Why?
|
Estrogen Receptor alpha | 1 | 2019 | 580 | 0.060 |
Why?
|
Culture | 1 | 2019 | 622 | 0.060 |
Why?
|
Paclitaxel | 1 | 2022 | 1716 | 0.060 |
Why?
|
Risk Assessment | 2 | 2021 | 24049 | 0.060 |
Why?
|
Research | 2 | 2023 | 1972 | 0.060 |
Why?
|
Fatal Outcome | 1 | 2019 | 1833 | 0.060 |
Why?
|
Philippines | 1 | 2024 | 91 | 0.060 |
Why?
|
Chi-Square Distribution | 1 | 2020 | 3469 | 0.060 |
Why?
|
Cardiovascular Diseases | 1 | 2020 | 15726 | 0.060 |
Why?
|
Cuba | 1 | 2024 | 48 | 0.060 |
Why?
|
Central America | 1 | 2024 | 64 | 0.060 |
Why?
|
Mastectomy, Segmental | 1 | 2019 | 963 | 0.060 |
Why?
|
Dominican Republic | 1 | 2024 | 74 | 0.060 |
Why?
|
Education, Medical, Continuing | 1 | 2019 | 828 | 0.060 |
Why?
|
Cisplatin | 1 | 2019 | 1643 | 0.050 |
Why?
|
BRCA2 Protein | 1 | 2018 | 797 | 0.050 |
Why?
|
Interviews as Topic | 1 | 2020 | 2649 | 0.050 |
Why?
|
Hospitalization | 1 | 2023 | 10732 | 0.050 |
Why?
|
Puerto Rico | 1 | 2024 | 373 | 0.050 |
Why?
|
Pneumonectomy | 1 | 2019 | 1109 | 0.050 |
Why?
|
Pyrazoles | 1 | 2022 | 1989 | 0.050 |
Why?
|
Medically Underserved Area | 1 | 2024 | 258 | 0.050 |
Why?
|
Leadership | 1 | 2021 | 1368 | 0.050 |
Why?
|
BRCA1 Protein | 1 | 2018 | 1146 | 0.050 |
Why?
|
Mexico | 1 | 2024 | 755 | 0.050 |
Why?
|
Bronchi | 1 | 2015 | 846 | 0.050 |
Why?
|
Mastectomy | 1 | 2019 | 1832 | 0.050 |
Why?
|
Menopause | 1 | 2019 | 1640 | 0.050 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2019 | 3518 | 0.050 |
Why?
|
Censuses | 1 | 2022 | 201 | 0.050 |
Why?
|
Thalidomide | 1 | 2016 | 885 | 0.050 |
Why?
|
Oligopeptides | 1 | 2016 | 1186 | 0.040 |
Why?
|
Adolescent | 3 | 2023 | 87551 | 0.040 |
Why?
|
Cyclophosphamide | 1 | 2016 | 2218 | 0.040 |
Why?
|
Masks | 1 | 2022 | 208 | 0.040 |
Why?
|
Advisory Committees | 1 | 2024 | 788 | 0.040 |
Why?
|
Bronchoscopy | 1 | 2015 | 902 | 0.040 |
Why?
|
Risk Factors | 2 | 2023 | 74167 | 0.040 |
Why?
|
Data Collection | 1 | 2018 | 3317 | 0.040 |
Why?
|
Developing Countries | 1 | 2022 | 2862 | 0.040 |
Why?
|
Receptor, erbB-2 | 1 | 2019 | 2524 | 0.040 |
Why?
|
Cancer Care Facilities | 1 | 2022 | 424 | 0.040 |
Why?
|
Disease-Free Survival | 1 | 2019 | 6814 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6530 | 0.040 |
Why?
|
Mammography | 1 | 2020 | 2449 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2018 | 5801 | 0.040 |
Why?
|
Dexamethasone | 1 | 2016 | 1927 | 0.040 |
Why?
|
Vulnerable Populations | 1 | 2024 | 696 | 0.040 |
Why?
|
Intensive Care Units | 2 | 2022 | 3730 | 0.040 |
Why?
|
Death | 1 | 2023 | 677 | 0.040 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 2801 | 0.040 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2023 | 1343 | 0.040 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 8548 | 0.040 |
Why?
|
Signal Transduction | 1 | 2020 | 23328 | 0.040 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2022 | 3960 | 0.040 |
Why?
|
Aged, 80 and over | 3 | 2023 | 58864 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2024 | 10329 | 0.030 |
Why?
|
Medically Uninsured | 1 | 2022 | 843 | 0.030 |
Why?
|
Health Facilities | 1 | 2022 | 576 | 0.030 |
Why?
|
Survival Analysis | 1 | 2019 | 10181 | 0.030 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 1708 | 0.030 |
Why?
|
Mass Screening | 1 | 2022 | 5419 | 0.030 |
Why?
|
Logistic Models | 1 | 2020 | 13309 | 0.030 |
Why?
|
Protein Kinase Inhibitors | 1 | 2022 | 5637 | 0.030 |
Why?
|
Health Personnel | 1 | 2019 | 3308 | 0.030 |
Why?
|
Kidney Diseases | 1 | 2016 | 2062 | 0.030 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2015 | 1453 | 0.030 |
Why?
|
Recurrence | 1 | 2016 | 8465 | 0.030 |
Why?
|
Treatment Outcome | 1 | 2020 | 64867 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2019 | 8489 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2018 | 5214 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2019 | 6436 | 0.030 |
Why?
|
Cause of Death | 1 | 2022 | 3719 | 0.020 |
Why?
|
Health Policy | 1 | 2023 | 2674 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2022 | 2617 | 0.020 |
Why?
|
Delirium | 1 | 2001 | 1653 | 0.020 |
Why?
|
Odds Ratio | 1 | 2022 | 9712 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2022 | 20461 | 0.020 |
Why?
|
Critical Care | 1 | 2001 | 2692 | 0.020 |
Why?
|
Insurance, Health | 1 | 2019 | 2500 | 0.020 |
Why?
|
Anxiety | 1 | 2001 | 4527 | 0.020 |
Why?
|
Medicare | 1 | 2023 | 6763 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2022 | 15815 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2019 | 36164 | 0.010 |
Why?
|
Young Adult | 1 | 2018 | 58477 | 0.010 |
Why?
|
Depression | 1 | 2001 | 8026 | 0.010 |
Why?
|
Colombia | 1 | 2001 | 272 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2019 | 39213 | 0.010 |
Why?
|
Psychotropic Drugs | 1 | 2001 | 882 | 0.010 |
Why?
|
Child | 1 | 2023 | 79604 | 0.010 |
Why?
|
Drug Utilization | 1 | 2001 | 1195 | 0.010 |
Why?
|
Cohort Studies | 1 | 2018 | 41266 | 0.010 |
Why?
|
Alcoholism | 1 | 2001 | 1952 | 0.010 |
Why?
|
Prospective Studies | 1 | 2001 | 54190 | 0.000 |
Why?
|
Concepts
(259)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(35)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_